Trends and outcomes of off-label use of transcatheter aortic valve replacement: Insights from the NCDR STS/ACC TVT registry

Keyphrases

• Transcatheter Aortic Valve Replacement 100%
• Off-label Use 100%
• TVT Registry 100%
• 1-year Mortality 17%
• United States 11%
• Hazard Ratio 11%
• 30-day Mortality 11%
• Adverse Outcomes 11%
• 1-year Outcome 11%
• Severe Aortic Stenosis 11%
• Off-label Indications 11%
• Clinical Practice 5%
• Medicaid 5%
• Medicare 5%
• U.S. Food 5%
• Adverse Cardiovascular Events 5%
• In-hospital Mortality 5%
• Severe Mitral Regurgitation 5%
• Subaortic Stenosis 5%
• Operative Risk 5%
• Severe Aortic Regurgitation 5%
• Transcatheter Valve Therapy Registry 5%
• Bicuspid Valve 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Off-Label Use 100%
• Adverse Outcome 50%
• Aortic Stenosis 50%
• Mitral Valve Regurgitation 25%
• Hospital Mortality 25%
• Aortic Regurgitation 25%
• Subvalvular Aortic Stenosis 25%

Medicine and Dentistry

• Percutaneous Aortic Valve Replacement 100%
• Off-Label Use 100%
• Hazard Ratio 11%
• Adverse Outcome 11%
• Aortic Stenosis 11%
• Cardiovascular System 5%
• Mitral Insufficiency 5%
• Medicare 5%
• Mitral Valve 5%
• Aortic Insufficiency 5%
• Surgical Risk 5%
• Hospital Mortality 5%
• Subvalvular Aortic Stenosis 5%